TG Therapeutics TGTX
TG Therapeutics reports $259.94 million revenue for Q3 2026
TG Therapeutics (TGTX) filed a 10-Q with the SEC on Nov 9, 2026, 4:33 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 15 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001628280-26-072257
- Revenue: $259.94 million for the three months ended Sep 30, 2026
- Net income: $55.46 million for the three months ended Sep 30, 2026
- Diluted EPS: $0.35 for the three months ended Sep 30, 2026
- Cash and equivalents: $429.38 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
15 new risk factors · 6 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $259.94M | $240.34M | +8.2% |
| Operating income and margin | $85.9M · 33% | $21.67M · 9% | +296%, margin +24 pts |
| Net income | $55.46M | $7.78M | +613% |
| Operating cash flow | $45.23M | $39.26M | +15% |
| Cash | $429.38M | $482.58M | −11% |
New risk factors (15)
- •favorable or unfavorable publicity relating to our products or relating to the Company.
- •unforeseen costs and expenses associated with creating a commercialization organization.
- •obtain, develop, maintain, protect, and defend our intellectual property portfolio; and
- •opportunities to acquire, license or invest in additional technologies, product candidates or businesses.
- •limiting our flexibility to plan for, or react to, changes in our business; and
- and 10 more in the filing
Removed risk factors (6)
- experience and expertise in exploitation of intellectual property rights; and capital resources.
- pay dividends and make contributions or repurchase our capital stock; and engage in certain transactions with affiliates.
- establishing commercially viable arrangements with third-party manufacturers for clinical supply and commercial manufacturing; and obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates.
- injunctions or the imposition of civil or criminal penalties; and adverse publicity.
- undergo changes in priorities or become financially distressed; or form relationships with other entities, some of which may be our competitors.
- and 1 more in the filing